Concentration of antipneumococcal antibodies as a serological correlate of protection: An application to acute otitis media

Journal of Infectious Diseases

Volumn 190, Issue 3, 2004, Pages 545-550

  Jokinen, Jukka T ^a   Åhman, Heidi ^b   Kilpi, Terhi M ^a   Mäkelä, P Helena ^a   Käyhty, M Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Wyeth Lederle Nordiska   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIUM CULTURE; CHILD; CLINICAL TRIAL; CORRELATION ANALYSIS; CROSS REACTION; GEOMETRY; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MIDDLE EAR; OTITIS MEDIA; PRIORITY JOURNAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

ACUTE DISEASE; ANTIBODIES, BACTERIAL; EAR, MIDDLE; HUMANS; INFANT; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 3242800477     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422531     Document Type: Article

References (12)

1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-95.
2. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-9.
3. Gardner S, Anderson D, Webb B, et al. Evaluation of Streptococcus pneuminiae type XIV opsonins by phagocytosis-associated chemiluminescence and bactericidal assay. Infect Immun 1982; 35:800-8.
4. Brown E, Hosea S, Frank M. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the blood-stream. Rev Infect Dis 1983; 5(Suppl 4):S797-805.
5. Gillespie S. Aspects of pneumococcal infection including bacterial virulence, host response and vaccination. J Med Microbiol 1989; 28:237-48.
6. Kilpi T, Åhman H, Jokinen J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children. Clin Infect Dis 2003; 37:1155-64.
7. Käyhty H, Åhman H, Rönnberg P-R, Tillikainen R, Eskola J. Pneumococcal polysaccharide - meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995; 172:1273-8.
8. Åhman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996; 15:134-9.
9. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Ser B 1977; 39:1-38.
10. Raftery AE. Approximate Bayes factors and accounting for model uncertainty in generalised linear models. Biometrika 1996; 83:251-66.
11. Jódar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21:3265-72.
12. Mäkelä PH, Käyhty H, Leino T, et al. Long-term persistence of immunity after immunization with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22:287-92.